STADOL
LOE ApproachingNDANASALSPRAY, METERED
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STADOL is a nasal spray metered-dose formulation approved in 1991 as an NDA small molecule product by Bristol Myers Squibb. The specific indication and mechanism of action are not publicly detailed in this dataset. The nasal route of administration suggests potential use in acute pain or migraine management.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team sizing and investment likely declining or stabilizing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
STADOL currently has zero linked job openings, indicating minimal active hiring or team expansion. Roles on this product focus on maintaining market share and managing the transition to generic competition rather than driving growth.
Brand ManagerField Sales Representative
Worked on STADOL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.